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Abstract  
The  lung  is  a  specialized  barrier  organ  that  must  tightly  regulate  interstitial  fluid  
clearance  and  prevent  infection  in  order  to  maintain  effective  gas  exchange.  Lymphatic  vessels  
are  important  for  these  functions  in  other  organs,  but  their  roles  in  the  lung  have  not  been  fully  
defined.  In  the  present  study,  we  addressed  how  the  lymphatic  vasculature  participates  in  lung  
homeostasis.  Studies  using  mice  carrying  a  lymphatic  reporter  allele  revealed  that,  in  contrast  to  
other  organs,  lung  lymphatic  collecting  vessels  lack  smooth  muscle  cells  entirely,  suggesting  
that  forward  lymph  flow  is  highly  dependent  on  movement  and  changes  in  pressure  associated  
with  respiration.  Functional  studies  using  CLEC2-­deficient  mice  in  which  lymph  flow  is  impaired  
due  to  loss  of  lympho-­venous  hemostasis  or  using  inducible  lung-­specific  ablation  of  lymphatic  
endothelial  cells  in  a  lung  transplant  model  revealed  that  loss  of  lymphatic  function  leads  to  an  
inflammatory  state  characterized  by  the  formation  of  tertiary  lymphoid  organs  (TLOs).  In  
addition,  impaired  lymphatic  flow  in  mice  resulted  in  hypoxia  and  features  of  lung  injury  that  
resemble  emphysema.  These  findings  reveal  both  a  lung-­specific  mechanism  of  lymphatic  
physiology  and  a  lung-­specific  consequence  of  lymphatic  dysfunction  that  may  contribute  to  
chronic  lung  diseases  that  arise  in  association  with  TLO  formation.       
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Introduction  
The  lymphatic  vascular  system  transports  fluid,  immune  cells,  and  lipids  throughout  the  
body  to  prevent  tissue  edema,  facilitate  adaptive  immune  responses,  and  enable  efficient  fat  
handling.  The  lymphatic  network  is  typically  depicted  as  a  network  of  smaller  lymphatic  
capillaries  that  are  specialized  to  take  up  cells,  protein,  and  fluid,  as  well  as  larger  collecting  
lymphatics  that  are  designed  to  return  lymph  to  the  venous  system  and  facilitate  immune  
surveillance  in  secondary  lymphoid  organs  such  as  lymph  nodes.  Recent  studies  of  the  blood  
vascular  system  have  highlighted  molecular  and  structural  features  that  contribute  to  organ-­
specific  roles  of  these  vessels  such  as  the  blood-­brain  barrier,  liver  sinusoids,  and  the  bone  
marrow  hematopoietic  niche  (1).  With  the  exception  of  villus  lacteals  that  are  specialized  for  the  
uptake  and  transport  of  dietary  fats,  the  extent  to  which  the  lymphatic  vascular  system  exhibits  
similar  organ-­specific  structure  and  function  at  other  sites  in  the  body  remains  unclear.    
  Lymphatic  vessels  are  relatively  abundant  in  the  lung,  an  organ  that  is  uniquely  
sensitive  to  edema  and  inflammation  that  may  impair  gas  exchange.  In  the  developing  lung,  
lymphatic  function  is  required  to  drain  fluid  and  achieve  the  compliance  that  is  necessary  for  
neonatal  lung  inflation  (2,  3),  but  the  role  of  lymphatics  in  the  mature  lung  is  undefined.  One  
proposed  role  of  pulmonary  lymphatics  is  to  drain  fluid  from  the  lung  in  order  to  prevent  
pulmonary  edema  that  would  reduce  gas  exchange.  However,  in  the  canonical  physiologic  
model  proposed  by  Ernest  Starling,  fluid  balance  in  the  lung  is  maintained  by  a  balance  of  
hydrostatic  forces  that  move  fluid  from  the  blood  and  into  the  interstitium  with  oncotic  forces  that  
move  fluid  from  the  interstitium  into  the  blood.  In  this  model,  lymphatics  are  not  required  to  
maintain  fluid  balance,  but  the  role  of  pulmonary  lymphatics  in  lung  fluid  homeostasis  has  yet  to  
be  fully  tested.  Short-­term  studies  using  catheter-­based  approaches  in  large  animals  have  
attempted  to  investigate  the  function  of  lymphatics  in  the  lung  (4),  but  lymph  flow  is  exceedingly  
slow  compared  to  flow  in  the  blood  circulation  (2ml/min  versus  5000ml/min  (5)).  Thus,  the  
consequences  of  changes  in  lymphatic  function  may  require  days  to  weeks  to  manifest.    
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The  lung  is  constantly  exposed  to  the  outside  environment,  and  must  maintain  both  a  
quiescent  immune  state  while  having  the  ability  to  generate  a  robust  immune  response  to  
pathogens  in  order  to  prevent  infection.  Immune  cell  trafficking  to  draining  lymph  nodes  via  the  
pulmonary  lymphatics  plays  a  central  role  in  coordinating  the  adaptive  immune  response  to  
infection  and  other  pathogens  (6,  7).  Chronic  inflammation  is  often  associated  with  the  
development  of  tertiary  lymphoid  organs  (TLOs),  also  known  as  inducible  bronchus-­associated  
lymphoid  tissue  (iBALT),  which  are  accumulations  of  lymphoid  cells  that  resemble  lymph  nodes  
in  cellular  content,  organization,  and  the  presence  of  lymphatic  vessels  (8,  9).  Although  TLOs  
are  a  hallmark  of  chronic  lung  disease  (10),  it  is  unclear  why  they  result  from  such  widely  
differing  insults  as  chronic  cigarette  smoke  exposure  and  infection.  Although  lymphatic  vessels  
and  lymphangiogenesis  are  key  features  of  TLOs  (8,  11),  whether  TLO  formation  is  connected  
to  lymphatic  function  is  unknown.  Finally,  although  abnormal  lymphatics  have  been  described  in  
association  with  a  variety  of  lung  diseases  (12),  whether  they  are  simply  a  consequence  of  the  
disease  or  whether  lymphatic  dysfunction  actively  contributes  to  lung  injury  is  unknown.    
To  address  the  role  of  lymphatics  in  the  adult  lung,  we  have  characterized  pulmonary  
lymphatic  anatomy  and  used  two  distinct  models  of  impaired  pulmonary  lymphatic  flow  in  the  
mouse:  CLEC2-­deficient  mice  in  which  blood  obstructs  the  forward  flow  of  lymph  in  the  lung  
(13),  and  mice  in  which  the  pulmonary  lymphatics  have  been  genetically  engineered  to  enable  
specific  deletion  following  lung  transplantation  using  diphtheria  toxin.  We  found  that  pulmonary  
collecting  lymphatics  have  valves  but  lack  smooth  muscle  cells,  a  unique  characteristic  of  these  
vessels  that  is  consistent  with  propulsion  of  lymph  through  respiration-­associated  changes  in  
thoracic  pressure  rather  than  contraction  of  the  vessel.  Functional  studies  demonstrate  that  
mice  with  impaired  pulmonary  lymphatic  flow  are  susceptible  to  increased  pulmonary  edema  
following  lung  injury,  and  develop  pronounced  leukocyte  accumulation  and  TLO  formation  in  the  
lung  parenchyma  even  in  the  absence  of  injury.  Unexpectedly,  mice  with  TLO  formation  
associated  with  impaired  lymphatic  flow  developed  hypoxia  and  lung  injury  with  several  features  
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of  human  emphysema.  These  findings  identify  unique  physiological  and  pathological  aspects  of  
lymphatic  function  in  the  lung  and  suggest  that  lymphatic  dysfunction  may  play  a  role  in  the  
pathogenesis  of  chronic  lung  disease.  
     
	   6	  
Results  
  
Pulmonary  collecting  lymphatics  lack  smooth  muscle  cell  coverage  
To  address  the  specific  roles  of  lymphatic  vessels  in  pulmonary  physiology  and  
pathophysiology,  we  first  carefully  examined  lung  lymphatic  vascular  anatomy.  The  lymphatic  
system  classically  consists  of  both  smaller  primary  lymphatic  capillaries  that  take  up  fluid,  
proteins,  and  cells  from  the  tissue  as  well  as  larger  collecting  vessels  that  transport  lymph  to  
lymph  nodes  and,  ultimately,  the  venous  system.  Whereas  lymph  flow  within  lymphatic  
capillaries  is  passive,  the  collecting  lymphatics  are  typically  characterized  by  the  presence  of  
functional  units  known  as  lymphangions  that  actively  pump  lymph  (14).  Lymphangions  consist  of  
smooth  muscle  cell  (SMC)-­lined  segments  of  lymphatic  vessel  separated  by  valves  (15).  
Physiologic  studies  of  collecting  lymphatics  from  the  limb  and  mesentery  have  demonstrated  
that  active  SMC  contraction  and  valve  activity  are  coordinated  to  create  waves  of  forward  
movement  of  lymph  (16-­19).  In  the  lung  however,  physiologic  studies  using  catheter-­based  
measurement  of  pulmonary  lymph  flow  in  anesthetized  large  animals  have  suggested  that  
extrinsic  forces  such  as  changes  in  thoracic  pressure  associated  with  respiration  may  play  a  
more  central  role  (3,  4,  20-­22).    
To  characterize  the  pulmonary  lymphatic  network  and  to  compare  it  to  better  
characterized  lymphatic  beds  such  as  those  in  the  gut  and  mesentery,  we  performed  whole  
mount  imaging  of  lungs  from  Prox1-­EGFP  mice  in  which  lymphatic  endothelial  cells  are  marked  
by  GFP  expression  (23).  Whole  mount  immunostaining  for  smooth  muscle  actin  (SMA)  revealed  
complete  coverage  of  arterial  vessels  and  characteristic  partial  coverage  of  bronchi,  but  virtually  
no  SMA  staining  was  detected  on  pulmonary  lymphatic  vessels  (Figure  1A,B).  Even  the  largest  
lymphatic  collecting  vessels  in  the  lung,  identified  by  their  more  proximal  location  adjacent  to  
large  airways  and  blood  vessels  (Figure  1A)  as  well  as  by  the  presence  of  PROX1hi  endothelial  
cells  that  mark  lymphatic  valves  (Figure  1B),  were  devoid  of  all  SMA  staining.  Using  
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conventional  immunohistochemistry  of  lung  sections,  SMA  staining  could  be  seen  lining  airways  
but  neither  SMA  nor  the  pericyte  marker  NG2  were  detectable  alongside  lymphatic  endothelium  
marked  by  VEGFR3  or  LYVE1  expression  (Figure  1C,D).  Prior  studies  have  reported  SMA  
staining  alongside  LYVE1+  endothelial  cells  (24),  but  careful  analysis  of  LYVE1  staining  
revealed  that  unlike  VEGFR3  staining,  LYVE1  was  readily  detected  in  large  blood  vessels  and  
capillaries  in  the  lung  and  therefore  does  not  independently  serve  as  a  specific  marker  of  lung  
lymphatic  vessels  (Figure  1C,D  and  Supplemental  Figure  1).  Analysis  of  180  distinct  lung  
lymphatic  vessels  identified  using  VEGFR3  staining  from  6  different  animals  revealed  no  
associated  SMA+  cells  (Supplemental  Table  1).  In  contrast,  collecting  lymphatics  in  other  tissues  
such  as  the  skin  (Figure  1E)  and  diaphragm  (Figure  1F)  exhibited  robust  SMC  coverage  in  non-­
valvular  regions,  consistent  with  classic  lymphangion  anatomy  (16,  19).  Importantly,  
immunostaining  of  collecting  lymphatic  vessels  in  normal  human  lung  tissue,  identified  by  
expression  of  the  lymphatic  endothelial-­specific  marker  PODOPLANIN  (25,  26),  also  showed  a  
lack  of  lymphatic  SMC  coverage  (Figure  1G,H).  These  results  reveal  that  collecting  lymphatic  
vessels  in  the  lung  have  a  unique  anatomy  in  which  the  classic  lymphangion  is  absent,  and  
suggest  that  lymph  flow  in  the  lung  does  not  rely  upon  intrinsic  pumping  of  the  collecting  
lymphatic  vasculature.  
  
Mice  lacking  CLEC2  exhibit  abnormal  pulmonary  lymphatic  morphology  and  function    
To  functionally  address  the  role  of  lymphatic  vessels  in  the  mature  lung  over  time,  we  
studied  animals  lacking  the  CLEC2  receptor  (27).  CLEC2  is  expressed  predominantly  on  
platelets  and  its  activation  by  PODOPLANIN  expressed  on  the  surface  of  lymphatic  but  not  
blood  endothelial  cells  is  required  to  maintain  separation  of  the  venous  and  lymphatic  
vasculature  through  formation  of  a  platelet  plug  at  the  lympho-­venous  junction  (13,  27,  28).  In  
the  absence  of  CLEC2,  there  is  chronic  retrograde  flow  of  blood  from  the  higher  pressure  
venous  system  into  the  thoracic  duct  that  impairs  forward  lymph  flow  (29).  Given  the  close  
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physical  proximity  of  the  lympho-­venous  junction  to  the  site  at  which  the  pulmonary  lymphatic  
vasculature  drains  into  the  thoracic  duct,  we  hypothesized  that  lymph  flow  in  pulmonary  
lymphatic  vessels  in  Clec2-­mutant  mice  would  be  significantly  compromised.  As  previously  
observed  in  mesenteric  lymphatics  (29),  loss  of  CLEC2  resulted  in  dilated  and  tortuous  
pulmonary  lymphatic  vessels  (visualized  using  the  Prox1-­EGFP  transgene  and  immunostaining  
for  VEGFR3)  compared  to  controls  by  4  weeks  of  age  (Figure  2A-­F).  We  have  previously  found  
that  impaired  lymph  flow  due  to  loss  of  CLEC2  is  associated  with  abnormal  mesenteric  
collecting  lymphatic  vessel  remodeling  characterized  by  increased  and  aberrant  smooth  muscle  
cell  recruitment  (29).  Consistent  with  prior  observations  in  the  mesentery,  increased  smooth  
muscle  cell  coverage  was  observed  on  pulmonary  lymphatics  in  4-­8  week  old  Clec2-­/-­  mice  but  
not  on  pulmonary  lymphatics  in  control  animals  (Figure  2G-­I).    
  
Since  constitutive  CLEC2  deficiency  may  lead  to  altered  lymphatics  due  to  loss  of  flow-­
dependent  lymphatic  vessel  remodeling  such  as  valve  formation,  as  well  as  impaired  lymph  
node  development  (29,  30),  we  next  assessed  pulmonary  lymphatic  function  in  mature  mice  
(aged  8-­10  weeks)  in  which  a  conditional  Clec2  allele  (31)  was  inducibly  deleted  following  
tamoxifen  administration  using  a  Rosa26CreERT2  driver  (Clec2fl/fl;;Rosa26CreERT2,  hereafter  
referred  to  has  iClec2  KO).  As  observed  in  Clec2-­/-­  animals,  iClec2  KO  mice  exhibit  reduced  
lymph  flow  due  to  loss  of  lymph-­venous  hemostasis  and  retrograde  filling  of  the  lymphatic  
network  with  blood  that  impairs  forward  lymph  flow  (13).  To  measure  pulmonary  lymphatic  flow,  
AlexaFluor568-­labelled  dextran  was  administered  intra-­tracheally  and  subsequently  detected  in  
the  mediastinal  lymph  nodes  that  drain  the  pulmonary  lymphatics  (32,  33).  Drainage  of  
AlexaFluor568-­dextran  to  mediastinal  lymph  nodes  was  significantly  decreased  in  iClec2  KO  
animals,  assessed  by  both  visual  examination  of  the  lymph  nodes  using  fluorescent  microscopy  
(Figure  2J,  K)  and  by  quantification  of  lymph  node  fluorescence  (Figure  2L),  consistent  with  
impaired  pulmonary  lymphatic  function.  Since  Clec2-­/-­  animals  and  iClec2  KO  animals  share  a  
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common  lymph-­venous  pathology,  these  studies  suggest  that  the  findings  in  the  Clec2-­/-­  animals  
described  above  arise  due  to  loss  of  lymphatic  flow.  However,  since  lymphatic  valve  
development  requires  lymph  flow,  the  observation  that  pulmonary  lymphatics  in  Clec2-­/-­  mice  
have  valves  (Figure  2B,C)  indicates  some  residual  lymph  flow  in  these  animals  (29).    
  
CLEC2  deficiency  results  in  formation  of  tertiary  lymphoid  organs  in  the  lung    
In  addition  to  drainage  of  extracellular  fluid,  lymphatics  serve  as  conduits  for  immune  cell  
migration  from  the  lungs  to  draining  lymph  nodes,  where  responses  to  infection  and  
inflammation  are  coordinated  (34,  35).  By  4  weeks  after  birth,  peribronchovascular  infiltrates  
were  observed  in  the  lungs  of  Clec2-­/-­  mice  but  not  in  the  lungs  of  control  littermates  (Figure  3A-­
C).  These  infiltrates  arose  in  close  physical  proximity  to  the  dilated  pulmonary  lymphatic  vessels  
in  Clec2-­/-­    lungs  (Figure  3D,E)  and  were  not  observed  in  littermate  control  lungs  at  any  time  
point  (Figure  3M).  Flow  cytometry  and  immunohistochemistry  of  lung  tissue  from  8-­12  week  old  
Clec2-­/-­  mice  revealed  a  significant  increase  in  the  number  CD11c+CD103+  dendritic  cells  as  well  
as  B220+  B  cells  compared  to  control  lungs  (Figure  3I,J).  An  increase  in  CD3+  T  cells  was  also  
observed  in  Clec2-­/-­    lungs  (Supplemental  Figure  3).  The  cellular  organization  and  location  of  
these  inflammatory  infiltrates  was  typical  of  tertiary  lymphoid  organs  (TLOs).  TLOs,  also  known  
as  bronchus-­associated  lymphoid  tissue  (iBALT),  form  in  response  to  chronic  inflammation  (10,  
36).  TLOs  resemble  secondary  lymphoid  tissue  in  their  organization,  and  a  hallmark  of  TLOs  is  
the  presence  of  high  endothelial  venules  (HEVs),  specialized  blood  vessels  that  are  found  
exclusively  in  lymphoid  tissue  that  enable  homing  of  leukocytes  to  that  site  from  the  blood  (9,  
10).  Consistent  with  their  identification  as  TLOs,  the  inflammatory  infiltrates  in  8-­12  week  old  
Clec2-­/-­  lungs  were  organized  around  cells  expressing  peripheral  lymph  node  addressin  (PNAd,  
Figure  3K,L),  a  specific  marker  of  high  endothelial  venule  endothelium  (37).  Importantly,  TLO  
formation  was  not  detected  in  other  tissues  in  Clec2-­/-­  mice  at  baseline,  even  in  organs  such  as  
the  gut  that  experience  a  loss  of  forward  lymphatic  flow  to  an  equal  or  greater  extent  as  that  
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observed  in  the  lungs  (29)  (Supplemental  Figure  4).  Whether  TLO  formation  occurs  in  other  
organs  in  Clec2-­/-­  mice  in  response  to  infection  or  inflammation  is  not  known.  
The  observation  that  TLOs  form  in  proximity  to  dilated  lymphatic  vessels  in  CLEC2-­
deficient  animals  suggested  that  they  arise  due  to  impaired  lymphatic  function.  However,  since  
CLEC2  is  also  expressed  on  dendritic  cells  and  is  required  for  dendritic  cell  migration  and  lymph  
node  development  (30,  38),  it  is  possible  that  TLO  formation  reflects  a  requirement  for  CLEC2  in  
dendritic  cells  or  other  leukocytes  rather  than  a  loss  of  forward  lymph  flow.  To  address  this  
possibility,  we  examined  the  lungs  of  mice  with  platelet-­specific  loss  of  CLEC2  (Clec2fl/-­;;PF4Cre,  
hereafter  referred  to  as  plt-­Clec2  KO),  that  exhibit  impaired  lymphatic  flow  due  to  loss  of  
lympho-­venous  hemostasis  but  retain  dendritic  cell  expression  of  CLEC2  and  have  normal  
lymph  node  development  (29).  As  in  Clec2-­/-­  mice,  pulmonary  lymphatics  in  plt-­Clec2  KO  
animals  were  dilated  and  displayed  abnormal  smooth  muscle  cell  coverage  (Figure  4A-­F).  Plt-­
Clec2  KO  mice  also  developed  TLOs  in  the  lungs  with  histologic  features  that  were  
indistinguishable  from  those  observed  in  Clec2-­/-­  mice,  including  proximity  to  lymphatic  vessels,  
large  numbers  of  B  cells,  and  the  presence  of  PNAd+  HEVs  (Figure  4G-­O).  Flow  cytometry  of  
lung  tissue  from  plt-­Clec2  KO  mice  revealed  an  increase  in  CD11c+  leukocytes  compared  to  
control  lungs  (Figure  4P),  similar  to  what  was  seen  in  Clec2-­/-­  mice.  While  TLOs  were  
exceedingly  rare  in  control  lungs  (Figure  4  and  Supplemental  Figure  5),  they  were  found  
throughout  the  lungs  of  8-­12  week  old  plt-­Clec2  KO  mice  (Figure  4Q).  These  findings  support  
the  conclusion  that  impaired  lymph  flow  is  sufficient  to  cause  TLO  formation  in  the  lungs.    
     
CLEC2-deficient mice exhibit defects in the drainage of fluid and cells from the lung 
  We  have  previously  shown  that  lymphatic  drainage  of  interstitial  fluid  is  required  to  
increase  lung  compliance  prior  to  birth,  thereby  enabling  successful  neonatal  lung  inflation  (2).  
In  contrast,  a  classic  model  originally  proposed  by  Ernest  Starling  maintains  that  in  the  mature  
lung,  fluid  balance  is  maintained  by  opposing  osmotic  and  hydrostatic  pressures  in  blood  
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capillaries  and  surrounding  tissue  (39,  40).  In  this  model,  forces  that  would  move  fluid  from  the  
blood  into  the  interstitium  (i.e.  positive  capillary  blood  pressure,  positive  osmotic  pressure  of  
interstitial  fluid,  and  negative  interstitial  pressure  in  the  lung)  are  precisely  balanced  by  those  
that  would  move  fluid  from  the  interstitium  into  the  blood  (i.e.  positive  blood  osmotic  pressure),  
leaving  little  role  for  lymphatic  function.  Indeed,  some  large  animal  physiologic  studies  have  
revealed  a  relatively  minor  role  for  pulmonary  lymphatics  in  clearing  lung  fluid,  even  in  
conditions  of  pulmonary  edema  (3,  41,  42),  although  invasive  lymphatic  flow  measurements  
have  documented  increased  lymphatic  flow  rates  in  settings  of  chronic  edema  (43,  44).  Thus,  
whether  and  to  what  extent  lung  lymphatics  are  required  to  prevent  pulmonary  edema  in  the  
mature  lung  is  not  established.  We  did  not  find  any  increase  in  pulmonary  edema  in  plt-­Clec2  
KO  mice  at  baseline  using  wet-­to-­dry  ratio  (Figure  5A),  consistent  with  the  lack  of  histologic  
changes  indicative  of  edema  in  the  lungs  of  plt-­Clec2  KO  mice  (Figure  4H,I  and  data  not  
shown).  In  contrast,  plt-­Clec2  KO  but  not  control  mice  exhibited  significant  pulmonary  edema  
after  acid-­induced  lung  injury  (Figure  5A).  
The accumulation of leukocytes and TLO formation in mice with reduced lymphatic 
function due to CLEC2 deficiency suggested that a primary function of pulmonary lymphatics is 
to transport immune cells from the lungs to the draining mediastinal lymph nodes. Migration of 
leukocytes from the lungs to lymph nodes after infection is essential for the adaptive immune 
response (34, 45). However, the fact that TLO formation was observed in the lungs of CLEC2-
deficient mice in the absence of infection suggested that lymphatic function may be required for 
leukocyte trafficking from the lung even under healthy conditions. To measure trafficking, 
leukocytes labelled with cell trace violet (CTV) were administered to mice intra-tracheally and 
subsequently detected by flow cytometry in the lungs and draining mediastinal lymph nodes of 
control and iClec2 KO mice at least 4 weeks after tamoxifen treatment (45) (Figure 5B,C), a 
time point previously found to be associated with impaired pulmonary lymphatic flow (Figure 2J-
L). Migration of CTV-labelled leukocytes from the airways to mediastinal lymph nodes via 
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lymphatics was significantly decreased in iClec2 KO mice (Figure 5D,E). Consistent with this 
finding, increased numbers of leukocytes were detected following bronchoalveolar lavage of plt-
Clec2 KO mice compared to control animals (Supplemental Figure 6). In contrast, movement of 
leukocytes to mediastinal lymph nodes following intravenous administration was not affected in 
iClec2 KO mice (Figure 5F). These findings suggest that TLO formation in CLEC2-deficient 
mice results from accumulation of immune cells in the lungs due to loss of pulmonary lymphatic 
function that is required for immune cell egress under basal conditions. 
  
Lung-­specific  lymphatic  ablation  results  in  rapid  TLO  formation  in  the  lung  parenchyma  
The  studies  using  CLEC2-­deficient  animals  described  above  suggested  that  loss  of  
lymphatic  vascular  function  results  in  TLO  formation  specifically  in  the  lungs.  However,  because  
lymphatic  flow  is  systemically  impaired  in  CLEC2-­deficient  animals,  it  is  possible  that  TLO  
formation  resulted  from  global  changes  in  immune  cell  activation  and/or  migration  rather  than  a  
lung-­specific  requirement  for  lymph  flow.  Furthermore,  we  could  not  rule  out  the  possibility  that  
TLOs  formed  in  the  lungs  of  CLEC2-­deficient  mice  due  to  contact  with  blood  rather  than  as  a  
consequence  of  impaired  lymphatic  flow.  To  more  precisely  test  the  role  lymphatic  vascular  
function  in  the  lungs,  and  to  rule  out  any  unexpected  secondary  effects  from  blood-­filled  
lymphatics  in  CLEC2-­deficient  models,  we  sought  to  generate  mice  in  which  lymphatic  function  
could  be  specifically  ablated  in  the  adult  lung.  To  accomplish  this,  mice  expressing  both  Cre-­
inducible  diphtheria  toxin  receptor  (DTR)  (46)  and  tamoxifen-­inducible  Cre  recombinase  driven  
by  the  lymphatic-­specific  VEGFR3  promoter  (47)  (iDTR;;VEGFR3CreERT2)  were  used  as  donors  
for  lung  transplantation  (Figure  6A).  VEGFR3  expression  is  restricted  to  lymphatic  endothelial  
cells  in  the  mature  lung,  and  lineage  tracing  confirmed  that  the  VEGFR3CreERT2  transgene  is  
active  specifically  in  those  cells  (Supplemental  Figure  7).  Tamoxifen  administration  to  
iDTR;;VEGFR3CreERT2  mice  induces  expression  of  DTR  in  lymphatic  endothelial  cells  of  the  
donor  lungs,  rendering  all  lymphatic  endothelial  cells  in  the  lung  susceptible  to  cell  death  
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following  exposure  to  diphtheria  toxin  A  (DT).  The  left  lungs  from  donor  iDTR;;VEGFR3CreERT2  
mice  were  transplanted  into  control  littermates.  Although  lymphatic  vessels  were  not  surgically  
reconnected  after  lung  transplant,  studies  in  mice  and  large  animals  have  demonstrated  that  
lymphatic  drainage  is  reestablished  7-­21  days  after  transplantation  (33,  48,  49).  DT  was  
administered  21  days  after  transplantation  of  the  iDTR;;VEGFR3CreERT2  lung  to  ensure  that  
lymphatics  function  was  first  reestablished  in  the  transplanted  lungs  (Figure  6A).  Rejection  of  
the  transplanted  lung  was  prevented  by  back-­crossing  to  C57Bl/6  background  and  by  the  strict  
use  of  littermates  for  donor  and  recipient  animals.    
Immunostaining  of  the  iDTR;;VEGFR3CreERT2  lung  isografts  for  the  lymphatic  endothelial  
markers  LYVE1  and  PROX1  5  days  after  onset  of  DTA  administration  revealed  a  greater  than  
50%  loss  of  lymphatic  endothelial  cells  compared  to  control  transplanted  lungs  (Figure  6B-­D),  a  
finding  predicted  to  impair  lymphatic  function.  We  did  not  observe  any  significant  amount  of  
blood  in  the  lymphatics  of  control  transplanted  lungs  or  in  the  remaining  lymphatics  in  
transplants  with  DT-­mediated  lymphatic  deletion  (Supplemental  Table  2),  confirming  that  this  
model  does  not  result  in  retrograde  blood  flow  into  the  lymphatic  vessels  as  seen  in  CLEC2-­
deficient  mice.  Significantly,  abundant  TLO  formation,  marked  by  the  presence  of  large  numbers  
of  B220+  cells  and  PNAd+  HEVs,  was  observed  in  iDTR;;VEGFR3CreERT2    transplanted  lungs  that  
were  treated  with  DT  but  not  in  control  transplanted  lungs  with  intact  lymphatics  (Figure  6E).  
Strong  correlation  between  the  extent  of  lymphatic  endothelial  cell  loss  and  the  formation  of  
TLOs  was  observed,  as  greater  numbers  of  TLOs  were  detected  in  transplanted  lungs  that  
exhibited  greater  deletion  of  lymphatic  endothelial  cells  (Figure  6F).  The  TLOs  that  formed  after  
lymphatic  deletion  closely  resembled  those  in  the  lungs  of  plt-­Clec2  KO  mice  in  their  location,  
appearance,  and  cellular  composition  (Figure  7A-­P).  The  rapidity  with  which  TLOs  formed  after  
lymphatic  deletion  in  this  model  (within  5  days)  compared  to  those  in  CLEC2-­deficient  mice  (at  
least  4  weeks)  was  notable.  This  likely  reflects  the  effects  of  acute  and  severe  disruption  of  
lymphatic  flow  in  this  model,  as  opposed  to  the  more  mild  and  chronic  impairment  of  lymphatic  
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flow  conferred  by  loss  of  CLEC2.  These  results  provide  a  second  line  of  genetic  evidence  to  
support  the  conclusion  that  loss  of  lymphatic  function  in  the  lung  results  in  TLO  formation.    
  
Constitutive loss of CLEC2 results in an emphysematous lung phenotype 
TLO formation is commonly seen in chronic lung inflammation and is associated with 
diverse lung diseases in humans (10, 36), but whether TLO formation is connected to impaired 
lymphatic flow, and whether TLOs are a cause or a consequence of lung disease remains 
unclear (50, 51). The primary formation of TLOs in mice with impaired lymphatic flow allowed us 
to ask whether lymphatic impairment might lead to lung injury and pathology. Although TLOs 
formed as early as P35 in plt-Clec2 KO mice, we did not observe any significant lung 
parenchymal changes at this time point (Supplemental Figure 8). However, 6-8 month old plt-­
Clec2  KO  mice  exhibited  marked  alveolar  enlargement  similar  to  that  observed  in  the  human  
lung  disease  emphysema  (Figure  8A-­C).  This  was  not  due  to  a  primary  defect  in  alveolarization  
in  these  mice,  as  there  was  no  appreciable  alveolar  enlargement  prior  to  P36  (Supplemental  
Figure  8),  a  time  point  by  which  alveolar  development  is  nearly  complete  (52).  The  
emphysematous  alveolar  phenotype  in  plt-­Clec2  KO  mice  was  associated  with  hypoxia,  an  
indicator  of  significant  impairment  of  lung  function  (Figure  8D).  A  hallmark  of  human  
emphysema  is  the  breakdown  of  elastin  in  the  alveolar  walls  due  to  secretion  of  degrading  
proteases  by  macrophages  and  neutrophils  (53,  54).  Immunostaining  revealed  reduced  elastin  
in  lungs  from  plt-­Clec2  KO  mice  compared  to  control  littermates,  particularly  in  areas  where  the  
emphysema  phenotype  was  most  pronounced  (Figure  8E,F).  Severe  emphysema  in  humans  is  
associated  with  the  generation  of  elastin  fragments  which  are  considered  a  marker  of  active  
disease  (55)  and  may  drive  disease  progression  (56-­58).  A  significant  increase  in  a  25kD  elastin  
fragment  and  a  nonsignificant  increase  in  a  45kD  elastin  fragment  was  detected  in  the  lungs  of  
6-­8  month  old  plt-­Clec2  KO  mice  compared  to  control  animals  (Figure  8G,H  and  Supplemental  
Figure  9).  Expression  of  the  elastin-­degrading  matrix  mettaloproteinase-­12  (MMP-­12)  is  
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required  for  the  development  of  cigarette  smoke-­induced  emphysema  in  mice  and  is  
upregulated  in  humans  with  this  disease  (53,  59,  60).  Increased  MMP-­12  was  detected  in  the  
lungs  of  mice  with  loss  of  CLEC2  by  both  qPCR  and  immunohistochemistry  (Figure  8I-­K).  Since  
the  only  described  effect  of  CLEC2-­deficiency  on  the  lung  is  impaired  lymphatic  flow,  these  
results  suggest  that  chronic  loss  of  lymphatic  function  is  sufficient  to  confer  a  lung  phenotype  
with  molecular  and  cellular  features  of  emphysema.  
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Discussion            
  
Organ-­specific  roles  have  recently  emerged  as  a  central  mechanism  by  which  the  
vascular  system  functions  in  both  healthy  and  diseased  states  (61),  but  designing  studies  to  
identify  these  roles  in  the  lymphatic  system  is  challenging  due  to  the  lack  of  organ-­specific  
lymphatic  markers  and  tools  to  target  the  lymphatic  vasculature  of  a  particular  organ.  The  
present  studies  identify  unique  anatomic  and  functional  features  of  pulmonary  lymphatic  
vessels.  The  finding  that  lymphatic  vessels  lack  smooth  muscle  cell  coverage  is  unique  to  the  
lung  and  suggests  that  pulmonary  lymph  flow  is  maintained  by  other  mechanisms,  e.g.  
respiratory  movements  and  changes  in  thoracic  pressure.  The  inability  of  lung  collecting  
lymphatics  to  independently  pump  lymph  may  make  these  vessels  uniquely  susceptible  to  
blockage  and  dysfunction.  Consistent  with  this  idea,  we  observed  that  following  global  
impairment  of  lymphatic  function,  spontaneous  formation  of  TLOs  occurs  specifically  in  the  lung.  
We  propose  that  these  unique  anatomical  and  functional  features  are  connected,  and  that  they  
may  link  changes  in  lymphatic  vessel  function  to  the  pathogenesis  of  common  lung  diseases.    
In  the  present  study,  we  used  two  distinct  approaches  to  examine  loss  of  pulmonary  
lymphatic  function  in  the  mouse:  genetic  deletion  of  CLEC2,  a  platelet  receptor  required  to  
maintain  forward  pulmonary  lymph  flow,  and  the  transplantation  of  lungs  genetically  engineered  
to  allow  inducible  ablation  of  lymphatic  endothelial  cells.  The  findings  using  these  two  models  
are  highly  concordant,  and  demonstrate  a  lung-­specific  role  for  lymphatic  vessels  in  preventing  
a  chronic  inflammatory  state  characterized  by  the  formation  of  TLOs.    We  also  find  that  
chronically  impaired  lymphatic  flow  due  to  loss  of  CLEC2  results  in  alveolar  enlargement  and  
hypoxia  with  features  of  lung  injury  that  resemble  emphysema.  These  findings  establish  an  
organ-­specific  role  for  lymphatic  vessels  in  the  lung,  and  suggest  that  impairment  of  lung  
lymphatic  function  may  participate  in  the  pathogenesis  of  lung  diseases  such  as  emphysema  
that  are  associated  with  TLO  formation.  
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An  established,  and  often  considered  universal,  role  of  lymphatic  vessels  is  to  take  up  
interstitial  fluid  and  proteins  that  leak  from  the  blood  vasculature,  thereby  preventing  tissue  
edema.  Consistent  with  this  role,  a  hallmark  sign  of  generalized  loss  of  lymphatic  function  is  
tissue  edema  (62),  and  lymphatic  function  is  required  for  fluid  drainage  in  the  developing  lung  to  
enable  neonatal  lung  inflation  (2).  Although  large  animal  studies  using  short-­term  catheter-­
based  approaches  have  demonstrated  that  lymphatic  flow  in  the  lung  may  be  dynamic  (21,  22)  
pulmonary  edema  can  also  be  considered  a  consequence  of  imbalanced  Starling  forces  in  the  
alveolar  blood  capillary  rather  loss  of  lung  lymphatic  function  (63).  Our  studies  of  CLEC2-­
deficient  lungs  provide  a  first  genetic  insight  into  the  long-­term  role  of  lymphatic  vessels  in  the  
management  of  fluid  homeostasis  in  the  mature  lung.    Lung  wet-­to-­dry  ratios  were  not  elevated  
in  CLEC2-­deficient  lungs  at  baseline.  Though  this  is  an  insensitive  measure  of  pulmonary  
edema,  the  absence  of  histologically  apparent  edema  in  the  lungs  of  CLEC2-­deficient  mice  
suggests  that  any  pulmonary  edema  that  results  from  impaired  lymphatic  drainage  is  unlikely  to  
be  severe  in  the  otherwise  healthy  lung.    However,  we  did  observe  increased  wet-­to-­dry  ratio  in  
response  to  lung  injury  in  CLEC2-­deficient  mice,  indicating  that  lymphatic  dysfunction  does  
contribute  to  pulmonary  edema  in  this  setting  and  establishing  a  role  for  pulmonary  lymphatics  
in  lung  fluid  management.  Future  studies  addressing  pulmonary  lymphatic  function  in  other  
pathologic  settings  are  likely  to  shed  additional  light  on  this  role.  
The  most  prominent  effect  of  impaired  pulmonary  lymphatic  function  observed  in  these  
studies  was  the  formation  of  TLOs,  a  pathology  detected  following  both  loss  of  CLEC2  and  LEC  
ablation  in  transplanted  lungs.    Since  these  in  vivo  models  share  no  molecular  or  cellular  
features  other  than  loss  of  lymphatic  function,  this  phenotype  is  highly  likely  to  be  a  specific  
consequence  of  lymphatic  impairment.  This  conclusion  is  also  supported  by  the  fact  that  TLOs  
were  observed  adjacent  to  collecting  lymphatic  vessels.  Moreover,  although  CLEC2-­deficient  
mice  experience  loss  of  mesenteric  and  intestine  lymphatic  function  that  is  similar  in  magnitude  
to  that  in  the  lung  (29),  TLOs  are  selectively  observed  in  the  lungs  of  CLEC2-­deficient  mice.  
	   18	  
Why  does  loss  of  lymphatic  function  result  in  TLO  formation  specifically  in  the  lung?  One  
possible  explanation  for  this  organ  specificity  is  that  pulmonary  lymphatic  vessels  transport  a  
larger  number  of  immune  cells  than  lymphatic  vessels  in  other  organs  due  to  the  fact  that  the  
lung  is  a  barrier  organ  exposed  to  the  outside  environment.  An  alternative  explanation  is  
suggested  by  the  unique  anatomy  of  pulmonary  lymphatic  collecting  vessels  that  lack  virtually  
all  SMC  coverage.  The  lack  of  SMC  coverage  may  make  pulmonary  collecting  lymphatics  more  
permeable  than  those  in  other  organs  and  facilitate  cellular  extravasation  when  lymph  flow  is  
impeded  (e.g.  the  CLEC2  KO  model)  or  when  the  lymphatic  endothelial  barrier  is  disrupted  (e.g.  
the  LEC  ablation  model).  In  either  case,  the  fact  that  lymphatic  impairment  is  sufficient  to  confer  
TLO  formation  in  an  otherwise  healthy  lung  suggests  that  changes  in  lymphatic  function  may  
play  an  important  role  in  lung  pathology.  
TLO  formation  is  a  common  histologic  feature  of  chronic  lung  inflammation  that  is  
observed  in  emphysema,  lung  transplant  rejection,  and  pulmonary  complications  of  rheumatoid  
arthritis  (64-­66).  However,  whether  TLO  formation  is  a  cause  or  consequence  of  these  disease  
processes  has  not  been  clear.  In  CLEC2-­deficient  mice,  TLO  formation  in  the  lung  is  an  early  
event  that  is  followed  by  evidence  of  lung  injury  characterized  by  alveolar  enlargement,  
breakdown  of  tissue  elastin,  and  significant  hypoxia  -­  all  features  of  cigarette  smoke-­induced  
emphysema  in  humans.  The  clear  temporal  sequence  of  these  events,  and  the  fact  that  platelet  
CLEC2  deficiency  appears  to  only  impact  the  lung  indirectly  through  changes  in  lymph  flow,  
suggest  that  TLO  formation  may  be  a  causal  mechanism  in  lung  injury,  and  that  lymphatic  
dysfunction  may  underlie  both  TLO  formation  and  lung  disease  pathogenesis.  The  fact  that  
abnormal  lymphatic  vessels  have  been  observed  in  a  variety  of  chronic  lung  diseases  (12)  
provides  additional  evidence  for  considering  this  possibility.  Future  studies  will  address  the  
precise  role  of  lymphatic  function  in  the  pathogenesis  of  common  lung  diseases  associated  with  
TLO  formation,  and  how  cigarette  smoke  exposure  may  directly  affect  lymphatic  vessel  function.  
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Methods  
Animal  models  
Clec2-­,  Clec2fl,  PF4-­Cre,  and  Prox1-­EGFP  BAC  transgenic  mice  have  been  previously  
described  by  our  lab  (23,  29)  and  were  maintained  on  a  mixed  background.  Rosa26-­iDTR  and  
Rosa26-­iYFP  mice  were  purchased  from  Jackson  Laboratory.  VEGFR3CreERT2  mice  (a  gift  from  
Sagrario  Ortega)  have  been  previously  described  (47).  For  transplant  experiments,  all  mice  
were  maintained  on  C57Bl/6  background.  For  all  experiments,  both  male  and  female  mice  were  
used.  
  
Whole  mount  staining  
Tissue  from  mice  carrying  the  Prox1-­EGFP  transgene  was  fixed  overnight  in  4%  PFA  at  4oC.  
For  lungs,  thick  coronal  sections  were  made  using  a  scalpel.  Other  tissues  were  stained  intact.  
Tissue  was  permeabilized  in  0.1%  BSA  +  0.3%  Triton-­X  in  PBS.  Incubation  with  Cy3-­conjugated  
anti-­smooth  muscle  actin  antibody  (Sigma,  C6198)  was  performed  in  0.3%  Triton-­X  in  PBS.  The  
tissue  was  imaged  using  a  Leica  TCS  SP8  confocal  microscope.    
  
Dextran  Assay  
50ul  of  5mg/ml  dextran-­568  (10,000kD  MW,  ThermoFisher)  was  administered  to  anesthetized,  
intubated  mice  via  endotracheal  catheter.  Fifty  minutes  after  administration,  the  mice  were  
sacrificed  for  harvest  of  mediastinal  lymph  nodes.  This  time  point  is  based  both  on  previous  
reports  using  this  assay  (33)  and  our  own  studies  demonstrating  the  time  course  of  dextran  
drainage  to  the  mediastinal  lymph  nodes  after  intra-­tracheal  delivery  (Supplemental  Figure  2).  
Lymph  nodes  were  imaged  using  an  Olympus  SZX16  dissecting  microscope.  Quantification  of  
fluorescence  intensity  was  performed  using  ImageJ.  
  
Immunohistochemistry    
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Mice  were  sacrificed  and  tissue  was  perfused  with  PBS.  Lungs  were  inflated  with  4%  PFA  at  
constant  pressure  of  25  cm  H2O  prior  to  harvest  and  fixation  with  4%  PFA  overnight.  Slides  from  
paraffin-­embedded  sections  were  H&E  stained  or  immunostained  with  antibodies  for:  B220  
(Abcam,  ab  64100),  CD3  (Abcam,  ab16669),  PNAd  (BD  Biosciences,  553863),  Lyve-­1  (R&D  
Systems,  AF2125  Systems),  VEGFR3  (R&D  Systems,  AF743),  Prox1  (Abcam,  ab76696)  MMP-­
12  (Abcam,  ab128030),  CD31  (HistoBiotec,  DIA  310),  and  NG2  (Millipore,  AB5320).  Slides  of  
normal  human  lung  tissue  was  stained  with  antibodies  for  PODOPLANIN  (D240,  Abcam,  
ab77854).  Elastin  was  detected  using  Modified  Verhoeff  Van  Gieson  Stain  Kit  (Sigma).  
  
Cell  Tracing  Assay  and  Flow  Cytometry  
Splenocytes  were  isolated  from  wild-­type  mouse  spleens  and  cultured  overnight  with  100ng/ml  
LPS  and  5ug/ml  PHA  (Sigma).  The  cells  were  then  labeled  with  cell  trace  violet  (CTV,  Molecular  
Probes)  according  to  manufacturer  instructions.  1x107  CTV-­labeled  cells  were  administered  to  
anesthetized  and  intubated  mice  either  via  endotracheal  catheter  or  intravenously.  Lymph  
nodes  or  lungs  were  harvested  48  hours  after  administration  of  CTV-­labeled  cells.  Single  cell  
suspensions  were  stained  with  the  following  antibodies:  FITC-­conjugated  anti-­CD45  
(eBioscience,  11-­04551-­82),  PE-­Cy7-­conjugated  anti-­CD11c  (BD  Bioscience,  561022),  and  
PerCP/Cy5.5-­conjugated  anti-­CD103  (Biolegend,  121415).  Flow  cytometry  was  performed  using  
a  BD  FACSCanto,  and  analyzed  using  FlowJo  software.    
  
Bronchoalveolar  Lavage  
Mice  were  sacrificed  and  bronchoalveolar  lavage  (BAL)  was  then  performed  through  a  20-­
gauge  angiocatheter  (BD  Pharmingen,  San  Diego,  CA),  with  the  intra-­tracheal  instillation  of  1  ml  
phosphate-­buffered  saline  (PBS)  containing  an  anti-­protease  cocktail  (Sigma)  and  5  mM  EDTA  
given  in  0.5  ml  increments.  Total  leukocyte  cell  count  (cells/ml  BAL  fluid)  was  measured  using  a  
Coulter  Cell  and  Particle  Counter  (Beckman  Coulter,  Miami,  FL).    
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Quantitative  PCR  and  Western  Blotting  
Total  RNA  was  isolated  from  lung  tissue  using  RNEasy  Kit  (Qiagen).  cDNA  was  made  using  
Superscript  III  First-­Strand  Synthesis  System  (Invitrogen)  following  manufacturer  instructions.  
qPCR  analysis  of  gene  expression  was  performed  using  QuantStudio  6  Real-­Time  PCR  System  
and  SYBR  Green  PCR  Master  Mix  (Applied  Biosystems).  Analysis  of  relative  gene  expression  
was  carried  out  using  the  comparative  CT  method  (ΔCT)  using  GAPDH  as  the  reference  
housekeeping  gene.  Each  qPCR  reaction  was  performed  in  triplicate.  Western  blots  were  
performed  according  to  standard  protocols  and  probed  with  anti-­elastin  (Abcam,  ab21610)  and  
anti-­beta  actin  antibodies  (Abcam,  ab8226).  Blots  were  imaged  using  LI-­COR  Imaging  Systems  
and  quantified  using  ImageJ.  
  
Acute  Lung  Injury  
Mice  were  exposed  to  acid-­induced  lung  injury  as  previously  described  (67).  Briefly,  30µl  of  
0.1N  HCl  was  administered  to  anesthetized  and  intubated  mice  either  via  endotracheal  catheter.  
Anesthetized  mice  were  ventilated  for  1  hour  after  acid  administration,  at  which  time  they  were  
euthanized  for  tissue  harvest.  Left  lungs  were  weighed  immediately  after  removal  (wet  weight)  
and  again  after  drying  in  an  oven  at  55°C  for  48  hours  (dry  weight).  
  
Lung  Transplants  and  Pulmonary  Lymphatic  Ablation  
iDTR;;VEGFR3CreERT2  mice  were  used  as  donors  for  single  lung  transplant  into  control  
littermates.  Expression  of  the  DTR  is  induced  by  administering  tamoxifen  i.p.  for  five  
consecutive  days  prior  to  transplant.  The  heart-­lung  block  was  harvested  and  flushed  with  
heparin  and  saline.  The  left  lung  was  then  isolated.  The  recipient  mouse  was  anesthetized  with  
isoflurane,  intubated,  and  connected  to  a  ventilator.  The  mouse  was  then  placed  in  the  supine  
position  and  an  incision  made  at  the  left  chest  between  the  3rd  and  4th  ribs  to  expose  the  left  
pulmonary  artery  and  vein.  After  a  micro-­serrefine  clamp  (FST  18055)  was  placed  at  the  left  
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hilum,  transverse  incision  was  made  on  the  left  bronchus.  A  running  stitch  of  11-­0  suture  
(Ethilon  2881G)  was  used  for  end-­to-­end  anastomosis  of  donor  to  recipient  bronchus.  Donor  
pulmonary  artery  and  vein  were  connected  to  recipient  pulmonary  artery  and  vein  respectively  
end  to  side  using  the  same  11-­0  suture.    The  native  left  lung  was  removed  after  implantation  of  
the  donor  lung.  Lymphatic  deletion  in  transplanted  lungs  was  induced  21  days  after  transplant  
by  administering  5  g  of  DTA  (Sigma)  over  72-­hours  using  a  subcutaneous  pump  (Alzet).  
  
Assessment  of  Oxygen  Saturation  
Mice  were  anesthetized  using  isoflurane,  and  pulse  oximetry  was  performed  using  a  
MouseSTAT  (Kent  Scientific).  For  each  mouse,  oxygen  saturation  was  recorded  every  10  
seconds  for  1  minute,  and  these  values  were  averaged.  Mice  were  monitored  and  anesthesia  
was  adjusted  to  ensure  that  the  heart  rate  was  maintained  at  greater  than  400bpm  for  all  
measurements,  and  oxygen  saturation  was  being  consistently  detected.  
  
Statistics  
Quantification  of  TLOs  in  lung  tissue  was  performed  using  4X  images  (1.1  x  1.3mm),  with  at  
least  3  images  used  for  each  mouse.  TLOs  were  defined  as  discrete  leukocyte-­dense  
accumulations  on  H&E  sections  that  were  predominantly  B-­cells  or  had  PNAd+  HEVs  by  
immunohistochemistry  on  serial  sections.  Quantification  of  SMA  staining  on  VEGFR3+  
lymphatics  was  done  on  doubled  stained  slides  of  lung  tissue  from  control  mice.  30  randomly  
selected  VEGFR3+  lymphatic  vessels  were  imaged  at  20X  magnification,  and  each  vessel  was  
assessed  for  any  associated  SMA  staining.  Quantification  of  Prox1+Lyve1+  endothelial  cells  was  
performed  by  scoring  double  positive  nuclei  using  20X  images  of  immunostained  tissue  from  
lung  transplants.  At  least  10  randomly  selected  images  were  used  for  each  mouse.  
Quantification  of  mean  linear  intercept  was  performed  as  previously  described  (68).  Briefly,  the  
sum  of  the  lengths  of  lines  drawn  across  the  images  was  divided  by  the  number  of  intersections  
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between  alveolar  walls.  At  least  ten  20X  images  of  lung  tissue  from  each  mouse  were  used  for  
analysis.  Data  shown  are  expressed  as  mean  ±  SEM,  and  number  of  samples  per  condition  are  
indicated  in  figure  legends.  Statistical  significance  was  determined  by  unpaired  two-­tailed  
Student’s  t  test  or  ANOVA  using  Prism  statistical  software.  P  values  less  than  0.05  were  
considered  statistically  significant.  
  
All  animal  experiments  were  approved  by  The  University  of  Pennsylvania  Institutional  Animal  
Care  and  Use  Committee.  
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Figure 1: Pulmonary collecting lymphatics lack smooth muscle cell or pericyte 
coverage. (A,B) Whole mount imaging of lungs from adult Prox1-EGFP lymphatic 
reporter mice shows pulmonary lymphatic vessels (lv) in green, with asterisk indicating 
an area of Prox1hi endothelial cells that marks lymphatic valves. Note staining for 
smooth muscle actin (SMA, red) present on both the bronchi (br) and arteries (art). 
(C,D) Immunohistochemistry of lung sections shows pulmonary lymphatics in green 
using staining for VEGFR3 or Lyve1 (arrows). Staining for SMA (C, red) or NG2 (D, red) 
marks airways or blood vessels, respectively. Asterisks indicate the large airway (C) or 
blood vessel (D) in proximity to lymphatic vessels. (E,F) Whole mount staining for SMA 
(red) on lymphatic vessels in skin (E) and diaphragm (F) in Prox1-EGFP mice. (G,H) 
Human lung tissue sections were stained for the lymphatic molecular marker PDPN 
using the D240 antibody (red, arrows) and SMA (green), with arteries indicated by 
asterisk. Scale bars = 25µm. 
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Figure 2: CLEC2-deficient mice exhibit impaired lymphatic flow. (A-C) Whole 
mount imaging of pulmonary lymphatic vessels (green) using the lymphatic reporter 
Prox1-EGFP in 4-8 week old Clec2-/- and control mice is shown. (D-F) 
Immunohistochemistry of lung sections for VEGFR3 (green) shows lymphatic vessels in 
4-8 week old Clec2-/- and control mice. (G-I) Whole mount staining of pulmonary 
lymphatic vessels (Prox1-EGFP, green) in 4-8 week-old Clec2-/- and control mice for 
smooth muscle actin (SMA, red). (J,K) Fluorescence microscopy of mediastinal lymph 
nodes (mLN) from iClec2 KO and control mice 50 minutes after intra-tracheal 
administration of dextran-568 (red). (L) Quantification of dextran-568 uptake to 
mediastinal lymph nodes by mean fluorescence intensity (AU). Scale bars = 25µm. Data 
are representative of at least 5 mice in each group. All values are means ± SEM. 
P value calculated by Student’s t test. ***P < 0.001.  
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Figure 3: Loss of CLEC2 is associated with abnormal tertiary lymphoid organ 
(TLO) formation in the lung parenchyma. (A-C) H&E staining of lung tissue from 4-6 
week old Clec2-/- and control mice. Arrowheads indicate inflammatory infiltrates. (D,E) 
Staining for pulmonary lymphatic vessels (VEGFR3, green) and capillaries (PECAM, 
red). Arrowheads indicate dilated pulmonary lymphatic vessels in the lung of a Clec2-/- 
mouse. (F) Flow cytometry of lung tissue from 8-12 week old control (top) and Clec2-/-  
mice (bottom) for CD103+ CD11c+ cells. Samples were gated for CD45+ leukocytes. (G-
L) Immunohistochemistry for B cells (B220, green) and high endothelial venules (PNAd, 
red, arrows) in Clec2-/-  and control mice. (M) Quantification of TLOs in the lungs of 8-12 
week old Clec2-/- mice compared to control littermates per 4x (1.1 x 1.3mm) microscopic 
field. Data representative of at least 5 mice in each group. Scale bars in A and B = 
100µm. All other scale bars =  25µm. All values are means ± SEM. P value calculated 
by Student’s t test. ****  P  <0.0001.  
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Figure 4: Platelet-specific loss of CLEC2 results in abnormal pulmonary 
lymphatic morphology and TLO formation in the lung parenchyma. (A-C) Whole 
mount staining of pulmonary lymphatic vessels (Prox1-EGFP, green) in 6-8 week-old 
plt-Clec2 KO and control mice for smooth muscle actin (SMA, red). (D-F) 
Immunohistochemistry of sections from lung tissue for VEGFR3 (green) shows 
lymphatic vessels in 6-8 week old plt-Clec2 KO and control mice. (G-I) H&E staining of 
lung tissue from 8-12 week old plt-Clec2 KO and control mice. (J-O) 
Immunohistochemistry for B cells (B220, green) and high endothelial venules (PNAd, 
red) in plt-Clec2 KO and control mice. (P) Flow cytometry of lung tissue from control 
(left) and plt-Clec2 KO mice (right) for CD45+ CD11c+ cells. (Q) Quantification of TLOs 
in the lungs of 8-12 week old plt-Clec2 KO mice compared to control littermates per 4x 
(1.1 x 1.3mm) microscopic field. Data representative of at least 5 mice in each group. 
Scale bar in G and H = 100µm. All other scale bars =  25µm. All values are means ± 
SEM. P value calculated by Student’s t test. ****  P  <0.0001.  
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Figure 5: Loss of CLEC2 results in impaired drainage of fluid and cells from the 
lung. (A) Wet-to-dry ratios of control and plt-Clec2 KO lungs at baseline and in 
response to acid-induced lung injury (ALI). (B) Cell tracing experiment to assess 
lymphatic leukocyte trafficking from lungs to draining lymph nodes. Intra-tracheal 
administration of CTV-labeled leukocytes is followed by harvest of mediastinal lymph 
nodes (mLN) for flow cytometry. (C) Identification of CD45+ CTV+ leukocytes in the 
lungs (left) and mediastinal lymph nodes (right) 48 hours after intra-tracheal 
administration in wild-type mice. (D) Flow cytometry of mLN from iClec2 KO (right) and 
control (left) mice for CD45+ CTV+ leukocytes 48 hours after intra-tracheal 
administration. (E) Quantification of CTV+ leukocytes in control and iClec2 KO mLNs 
after intra-tracheal administration, as percent of total CD45+ leukocytes. (F) 
Quantification of CTV+ leukocytes in control and iClec2 KO mLNs after intravenous 
administration as percent of total CD45+ leukocytes. Data representative of at least 4 
mice in each group. All values are means ± SEM. P value calculated by Student’s t test. 
*  P  <0.05.  n.s.  =  not  significant.  
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Figure 6: Lung-specific lymphatic endothelial cell ablation leads to TLO 
formation. (A) Top: Schematic of the experimental approach used for lung-specific 
deletion of pulmonary lymphatics. Diphtheria toxin receptor (iDTR) expression is 
induced in lymphatic endothelial cells using a lymphatic endothelial cell-specific Cre 
(VEGFR3CreERT2). Lungs from iDTR;VEGFR3CreERT2 mice are used as donors for 
single lung transplant to littermate recipients, and administration of DT to transplanted 
mice leads to lymphatic endothelial cell death specifically in the transplanted lung, while 
control transplanted lungs have intact lymphatics. Bottom: Timeline of lung-specific 
lymphatic ablation in lung transplants. (B,C) Immunohistochemistry for Prox1+Lyve-1+ 
lymphatic endothelial cell (LEC) nuclei in control lungs (B, arrows) and lungs with DT-
mediated lymphatic ablation (C). (D) Quantification of Prox1+Lyve-1+ nuclei in DT-
treated iDTR;VEGFR3CreERT2 transplanted lungs comparied to control transplanted 
lungs. (E) Quantification of TLOs in DT-treated iDTR;VEGFR3CreERT2 transplanted 
lungs compared to control transplants per 4x (1.1 x 1.3mm) microscopic field. (F) 
Correlation of TLOs to number of Prox1+Lyve+ LEC nuclei in DT-treated 
iDTR;VEGFR3CreERT2 transplanted lungs. Data representative of 4 mice in each group. 
Scale bars = 25µm. All values are means ± SEM. *  P  <0.05.  P value calculated by 
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Figure 7: TLOs after lung lymphatic ablation resemble those in plt-Clec2 KO mice. 
(A-H) H&E staining of lung tissue from control transplanted lungs, DT-treated 
iDTR;VEGFR3CreERT2 transplanted lungs with lymphatic ablation, and lungs from plt-
Clec2 KO mice. (I-P) Immunohistochemistry for B cells (B220, green) and HEVs (PNAd, 
red) in control transplanted lungs, DT-treated iDTR;VEGFR3CreERT2 transplanted lungs, 
and plt-Clec2 KO lungs. Data representative of 4 mice in each group. Scale bars in A-D 
= 100µm. All other scale bars = 25µm.   
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Figure 8: CLEC2 deficiency results in reduced lung function associated with 
emphysematous changes. (A,B) H&E staining of lung tissue from 6-8 month-old plt-
Clec2 KO and control mice. (C) Quantification of alveolar enlargement in 6-8 month old 
plt-Clec2 KO and control mice by mean linear intercept (MLI). (D) Oxygen saturation in 
6-8 month old plt-Clec2 KO and control mice. (E,F) Van Gieson staining for elastin 
(black, arrows) in the lungs of control and plt-Clec2 KO mice. (G) Western blot of whole 
lung tissue for 25kD elastin fragment (EF) in 6-8 month-old plt-Clec2 KO and control 
mice. (H) Quantification of 25kD EF in western blots by fluorescence intensity (AU). 
Comparisons were made between matched littermates. (I) Quantitative PCR of lung 
tissue from plt-Clec2 KO and control mice for MMP-12. Comparisons were made 
between matched littermates. (J,K) Immunohistochemistry for MMP-12 (red) in lungs 
from plt-Clec2 KO and control mice. Data representative of at least 4 mice in each 
group. Scale bars = 25µm. All values are means ± SEM. P value calculated by 
Student’s t test. *  P  <0.05    **  P  <0.01.  
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